Enlivex Therapeutics (NASDAQ:ENLV) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of Enlivex Therapeutics (NASDAQ:ENLV) from a hold rating to a sell rating in a research note issued to investors on Saturday.

ENLV has been the topic of several other research reports. HC Wainwright increased their target price on Enlivex Therapeutics from $7.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enlivex Therapeutics in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $13.00.

Enlivex Therapeutics Stock Down 3.7%

ENLV opened at $1.05 on Friday. Enlivex Therapeutics has a 52 week low of $0.66 and a 52 week high of $2.10. The business has a fifty day simple moving average of $1.10 and a 200-day simple moving average of $1.02. The firm has a market cap of $249.25 million, a P/E ratio of -1.91 and a beta of 1.55.

Hedge Funds Weigh In On Enlivex Therapeutics

Several institutional investors have recently modified their holdings of the business. Citizens Financial Group Inc. RI acquired a new stake in shares of Enlivex Therapeutics in the third quarter valued at $241,000. Renaissance Technologies LLC boosted its holdings in Enlivex Therapeutics by 99.4% in the fourth quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after purchasing an additional 156,336 shares during the period. HRT Financial LP grew its stake in Enlivex Therapeutics by 719.4% during the 4th quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after purchasing an additional 135,198 shares in the last quarter. Jane Street Group LLC grew its stake in Enlivex Therapeutics by 527.4% during the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after purchasing an additional 67,886 shares in the last quarter. Finally, Invesco Ltd. purchased a new stake in Enlivex Therapeutics during the 4th quarter worth about $43,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.